NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
* Reuters is not responsible for the content in this press release.
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a
medical device company focused on developing products for minimally disruptive
surgical treatments for the spine, announced today that Kevin O'Boyle, Chief
Financial Officer and Executive Vice President, will present at the
Oppenheimer 20th Annual Healthcare Conference at The Waldorf Astoria Hotel in
New York, New York, on Tuesday, November 3, 2009.
A live webcast of the presentation will be available online from the investor
relations page of the Company's corporate website at www.nuvasive.com. After
the live webcast, the presentation will remain available on the website for 30
days.
About NuVasive
NuVasive is a medical device company focused on the design, development, and
marketing of products for the surgical treatment of spine disorders. The
Company's product portfolio is focused primarily on the $4.6 billion U.S.
spine implant market. Additionally, the Company has expanded into the $1.5
billion global biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum Access Surgery,
or MAS® platform. The MAS platform combines four categories of products that
collectively minimize soft tissue disruption during spine surgery with maximum
visualization and safe, easy reproducibility for the surgeon: NeuroVision®, a
proprietary software-driven nerve avoidance system; MaXcess®, a unique
split-blade retractor system; a wide variety of specialized implants; and
several biologic fusion enhancers. MAS significantly reduces surgery time and
returns patients to activities of daily living much faster than conventional
approaches. Having redefined spine surgery with the MAS platform's lateral
approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has
built an entire spine franchise. With nearly 50 products today spanning
lumbar, thoracic and cervical applications, the Company will continue to
expand and evolve its offering predicated on its R&D focus and dedication to
outstanding service levels supported by a culture of Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which, if they do
not materialize or prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties that could
cause actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or clearance
for NuVasive's products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require significant
changes to NuVasive's products or clinical studies; the risk that products may
not perform as intended and may therefore not achieve commercial success; the
risk that competitors may develop superior products or may have a greater
market position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's public filings
with the Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking statement to
reflect events or circumstances arising after the date on which it was made.
Contact: Investors:
Kevin C. O'Boyle Patrick F. Williams
EVP & Chief Financial Officer Vice President, Finance & Investor
NuVasive, Inc. Relations
858-909-1998 NuVasive, Inc.
investorrelations@nuvasive.com 858-638-5511
investorrelations@nuvasive.com
Media:
Jason Rando
The Ruth Group
646-536-7025
jrando@theruthgroup.com
SOURCE NuVasive, Inc.
Kevin C. O'Boyle, EVP & Chief Financial Officer, NuVasive, Inc.,
+1-858-909-1998, investorrelations@nuvasive.com; Investors: Patrick F.
Williams, Vice President, Finance & Investor Relations, NuVasive, Inc.,
+1-858-638-5511, investorrelations@nuvasive.com; Media: Jason Rando, The Ruth
Group, +1-646-536-7025, jrando@theruthgroup.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters